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SumlTlary 
Asthma is a chronic life-threatening disease of  worldwide importance. Although allergic asthma 
and related atopic conditions correlate strongly with immune sensitization to house dust mites, 
it is unclear why antigens from mites provoke such powerful allergic immune responses. We 
have characterized the protease activity of Der p  I, the group I protease allergen of the house 
dust mite Dermatophagoides pteronyssinus,  and here report that it cleaves the low-affinity immu- 
noglobulin (Ig) E Fc receptor (CD23) from the surface of human B lymphocytes. Derp I selec- 
tively cleaves CD23 and has no effect on the expression of any other B cell surface molecules 
tested. We speculate that this loss of cell surface CD23 from IgE-secreting B cells may promote 
and enhance IgE immune responses by ablating an important feedback inhibitory mechanism 
that normally limits IgE synthesis.  Furthermore, since soluble CD23 is reported to promote IgE 
production, fragments of CD23 released by Der p I may directly enhance the synthesis of IgE. 
cel-Antiprotease, a pulmonary antiprotease, is also shown to inhibit the cleavage of CD23 by 
Derp I. This may be significant in the etiopathogenesis of asthma, because other indoor pollut- 
ants associated with asthma are known to potently inhibit this antiprotease. These data suggest 
that the proteolytic activity of Derp I, the group I allergen of the house dust mite D. pteronyssi- 
nus, is mechanistically linked to the potent allergenicity of  house dust mites. Furthermore, inhi- 
bition of Der p I by cq-antiprotease suggests  a mechanism by which confounding factors, such 
as tobacco smoke, may act as a risk factor for allergic asthma. 
A 
llergic asthma is a worldwide problem of considerable 
clinical importance. Links between asthma and expo- 
sure to house dust and its microfauna have been recognized 
for  >300  yr  (1).  More  recently,  causal  links  have  been 
proven between immunity to house dust mites and allergic 
disorders,  including asthma,  rhinitis,  dermatitis,  and  con- 
junctivitis (2-5). 
House dust mites of the family Pyroglyphidae infest most 
homes  in  temperate  chmates.  In  the  United  Kingdom, 
three species,  Dermatophagoides pteronyssinus,  D. farinae,  and 
Euroglyphus  maynei,  commonly flourish in the indoor envi- 
ronment (6).  This is due,  in part,  to fuel-saving measures 
that reduce ventilation and create an ideal mite habitat of 
high humidity and temperature. Early exposure to the high 
levels of house dust mites encouraged by these conditions 
and  the  confounding  influence  of indoor  pollution  are 
widely blamed for recent rises in the incidence of allergic 
asthma (7). Despite this, it remains unclear why mites pro- 
voke such powerful allergic immune responses. It has been 
suggested that certain biochemical properties of an antigen 
may determine allergenicity (8). Enzymes in particular ap- 
pear to  be  potently allergenic  (9-15),  and  several of the 
well-characterized house dust mite allergens are known to 
be, or suspected of  being, enzymes (16--20). It is not under- 
stood, however, how and why this category of protein an- 
tigens consistently provokes allergic immune responses. 
Most individuals allergic to house dust mites possess IgE 
antibodies to the group I allergens of mites. The group I al- 
lergen ofD. pteronyssinus  (Derp I) a is a 30-kD protein con- 
taining sequences conserved in the active sites  of cysteine 
proteases  (16).  It is produced in  the midgut  of the  mite, 
where its role is probably related to the digestion of food 
substrates  in,  or associated with,  human  skin  (21).  Up  to 
0.2 ng of proteolytically active Der p  I is incorporated into 
the peritrophic membrane of each mite fecal pellet, 40 of 
1Abbreviations used in this  paper: APMSF, 4-[amidinophenyl]  methanesulfo- 
nyl fluoride;  Derp I, the group I allergen ofDermatophagoides  pteronyssinus; 
E64, t-trans-epoxysuccinyl-leucylamide-[4-guanidino]-butane;  sCD23, sol- 
uble CD23. 
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pellets vary in size between 10 and 40 I~m and are therefore 
ideal respirable delivery vehicles for Der p  I to the respira- 
tory tract (4). 
Events leading to the  development of allergic immune 
responses are controversial. In atopic individuals, allergen- 
activated CD4 +  Th2-1ike T  lymphocytes are  thought  to 
secrete high levels of cytokines such  as  IL-4, which pro- 
mote IgE synthesis by B cells (22-25). In nonallergic indi- 
viduals,  the immune response to the same antigens is sus- 
pected additionally to include Thl cytokines such as IFN-y. 
These may modulate the immune  response by inhibiting 
development of Th2-1ike T  cells and thus balance the cy- 
tokine profile of the response to prevent allergy. Most im- 
portant in the context of this study, however, is  that IgE 
synthesis may also  be controlled by a feedback inhibition 
mechanism  that  is  mediated  by  IgE-containing  immune 
complexes binding  to  the  low-affinity receptor for  IgE, 
CD23 on B cells. 
Several  cell  types  in  the  normal  individual,  including 
eosinophils, monocytes, B cells, and T  cells, express consti- 
tutively low levels of CD23. Activation of these cell types 
by inflammatory and infectious diseases or neoplastic trans- 
formation induces high-level CD23 expression (26, 27). In 
patients  with  asthma,  the  macrophages,  eosinophils,  and 
epithelial cells of the respiratory tract are also  reported to 
express high levels of CD23 constitutively (26-28). 
Unlike the other Fc receptors, CD23 is not a member of 
the  Ig  superfamily.  Instead,  the  molecule contains  a  cal- 
cium-dependent  lectin  domain  and  heptad  hydrophobic 
repeats, suggesting an c~-helical coiled structure more typi- 
cal  of the  selectin  and  asialoglycoprotein receptor family 
members  (29).  CD23  is a type II integral membrane pro- 
tein, the cytoplasmic NH  2 terminus of which, in humans, 
is  encoded  by  one  of two  alternate  exons  to  give  the 
CD23A  and  CD23B  isoforms  (30).  CD23A  is  develop- 
mentally regulated and expressed only by antigen-activated 
human B cells, whereas CD23B is expressed on many cell 
types in both humans and mice and is inducible with IL-4 
(30).  Monomeric  45-kD  CD23  monomers  associate  to 
form homotrimers at the cell surface (29,  31). The el-heli- 
cal  coils  of monomeric  CD23  are  predicted  to  form  a 
coiled-coil stalk  containing the transmembrane region. At 
the COOH terminus, the lectin heads, which are exposed 
to the extracellular environment, act as an Fc receptor by 
binding the  Ce3  domains of IgE  (29,  32).  In  addition  to 
binding to IgE, CD23 also interacts with CD21, the CR2 
(33).  This interaction may be important in homotypic ad- 
hesion between B cells, the enhancement of IgE synthesis, 
and the rescue of  germinal center B cells from apoptosis  (29). 
CD23 exerts its regulatory influence on the IgE network 
by  binding  IgE  and  IgE-containing immune  complexes. 
High  levels  of IgE-containing  immune  complexes  that 
bind to CD23 on the surface of IgE-secreting B cells trans- 
duce a feedback-inhibitory signal that prevents further IgE 
synthesis (27,  34, 35).  In the absence of CD23,  such as in 
CD23 knockout mice (35), this mechanism of feedback in- 
hibition is not present,  causing IgE levels to be increased 
and sustained in response to T  cell-dependent antigens. 
Immunoregulatory CD23  is  also  cleaved from the  cell 
surface by a mechanism that is not yet fully understood but 
that may involve proteolysis (36,  37).  Cleavage occurs in 
the  coiled stalk,  giving rise  to  trimeric fragments that re- 
solve at molecular weights  of 37,  33,  29,  25,  and  16 kD 
(36,  37).  These  soluble  CD23  (sCD23)  molecules  retain 
the IgE-binding lectin heads and thus bind to IgE. The in- 
creased expression of cell surface CD23 observed in inflam- 
matory, infectious, and neoplastic conditions is often mir- 
rored by an increased level of plasma sCD23 and IgE (38). 
This is most probably related to the activity of sCD23 as a 
pleiotropic cytokine. In parfcular, soluble fragments of  CD23 
>29 kD  are reported to enhance IgE synthesis  by B  cells 
(39-41). The mechanism ofsCD23-enhanced IgE synthesis 
probably involves sCD23 binding to surface membrane IgE 
and  CD21  (29),  but  because  sCD23-mediated  enhance- 
ment of IgE synthesis  is T  cell-independent, this mecha- 
nism only operates once T cell dependent Ig isotype switch- 
ing to IgE has taken place. 
Loss of CD23 from the cell surface or an increase in the 
level of  plasma sCD23 is thus highly proallergic. Any extra- 
neous agent changing the expression of cell surface CD23 
or the level of sCD23 may affect the regulation of IgE syn- 
thesis and hence the severity of allergic symptoms. 
To prevent proteolytic damage by infectious agents and 
activated inflammatory cells, the normal respiratory tract is 
protected by  antiproteases.  An  antiprotease  of the  serpin 
family, 0q-antiprotease, is largely responsible for inactivat- 
ing the endogenously produced neutrophil serine protease 
elastase and thus maintaining the protease-antiprotease bal- 
ance of the lung (42).  Hereditary abnormalities or xenobi- 
otic-induced damage that reduces the efficiency of this an- 
tiprotease is known to tip this balance and thus constitutes a 
powerful risk factor for lung disease,  including asthma,  by 
allowing the proteolytic products of macrophages and neu- 
trophils  to  predominate  (42,  43).  Similarly,  inhaled pro- 
teolytically active Der p  I  in mite fecal particles may also 
place the respiratory tract at risk of focal proteolytic attack. 
Reports on the increase in the incidence of asthma have 
focused on the influence ofcofactors that increase suscepti- 
bility to allergic asthma (44,  45). Of these, the indoor pol- 
lutants of tobacco smoke have received particular attention 
(46-48). Passive  or intentional exposure to such pollutants 
may inactivate cq-antiprotease either directly, by oxidation 
of an active center methionine residue at position 358,  or 
indirectly,  by  eliciting  and  activating  puhnonary  phago- 
cytes to produce oxidants with the same effects (42). 
Here we report that Der p  I,  a protease allergen of the 
house  dust  mite  D.  pteronyssinus,  cleaves  the  low-affinity 
IgE  Fc  receptor (CD23)  from B  lymphocytes. This  may 
deprive the B cell of an important mechanism to limit IgE 
synthesis  and generate fragments of CD23 that directly en- 
hance IgE synthesis.  Cleavage of CD23 is inhibited by oq- 
antiprotease,  suggesting that  environmental circumstances 
that  reduce the  efficiency of innate  antiprotease  defenses 
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cleaving CD23,  the  allergen may disregulate the  IgE  net- 
work, possibly contributing to the development of allergic 
asthma. Based on these data, we speculate that the biologi- 
cal activity of Der p  I may account for its potent allergenic- 
ity and  suggest  a  mechanism  by which  indoor  pollutants 
could act as a  confounding influence on the  development 
of allergic asthma caused by house dust mites. 
Materials  and Methods 
Purification Of Derp I.  Der p  I  was  purified from  laboratory 
cultures of D. pteronyssinus (49) by aflfinity chromatography using 
the anti-group I  mite allergen mAb, 4C1  (50)  (generously do- 
nated by Dr.  Martin  Chapman,  University of Virginia Health 
Sciences Center,  Charlottesville, VA) coupled to cyanogen bro- 
mide-activated Sepharose  4B.  Whole-mite  culture  (15  g)  was 
stirred for 16 h at 4~  in 200 ml PBS, pH 8.0. Debris and insolu- 
ble  material were  removed  by  centrifugation  at  13,000 g  and 
0.2-1~m filtration. The extract was applied to the affinity column, 
which was  washed  extensively with PBS,  pH  8.0.  Der p  I  was 
eluted with 50 mM glycine, 50% ethylene glycol, pI-I 10.0.  After 
dialysis against PBS, pH 8.0, Der p  I was concentrated to  1 mg/ 
m1-1 using an ultrafiltration unit  (Centriprep 10; Amicon, Bev- 
erly, MA)  and  stored at  -80~  Purity was  assessed by silver- 
stained 15% SDS-PAGE according to standard methods (51). Zy- 
mograms were run as for SDS-PAGE, with 1% evaporated milk 
included in  the  resolving gel  (52).  Once  run,  the  zymograms 
were incubated for 16  h  at 37~  in PBS,  pH  8.0,  followed by 
staining with Coomassie blue. 
Fluorogenic Substrate and Use of Enzyme Inhibitors.  The  fluoro- 
genic substrate FITC-casein was prepared according to standard 
methods (53) and used as follows: Der p  I  (7.5  Ixg/m1-1)  was in- 
cubated for 1 h  at 37~  with FITC-casein (250  Ixg/m1-1)  in 50 
mM  2-amino-2-methyl-l:3-propanediol-HC1, pH  8.0  (the  pH 
optimum for Derp I; data not shown). The reaction was stopped 
with TCA,  incubated at room temperature for 1 h,  and centri- 
fuged at 13,000 g for 30 min at 4~  The fluorescence of triplicate 
samples of supematant was then recorded at an excitation wave- 
length of 490  nm and an emission detection wavelength of 525 
nm.  I  lig of Der p I typically exhibited 0.06 tryptic U  of activity, 
equivalent to 300 fluorescent U. 
In experiments using protease inhibitors, proteases were prein- 
cubated at 37~  with the inhibitor for 30 rain before the addition 
ofsubstrate. The protease inhibitors L-trans-epoxysuccinyl-leucy- 
lamide-[4-guanidino]-butane (E64)  (Novabiochem, Nottingham, 
UK),  4-[amidinophenyl]  methanesulphonyl  fluoride  (APMSF) 
(Novabiochem),  pepstatin-A  (Novabiochem),  EDTA  (Sigma 
Chemical Co., Poole, Dorset, UK) and 1,10-phenanthroline (Nov- 
abiochem)  were  reconstituted as  recommended  by  the  manu- 
facturers and used over a  range of concentrations either side of 
those recommended (full data not shown). Recombinant human 
oq-antiprotease was  generously donated by Drs.  Rob  Stockley 
and Carol Llewellyn-Jones (University of Birmingham, Birming- 
ham, UK). 
Purification of lmmunoaflinityopurified Der p I on Thiol-Sepharose. 
Activated thiol-Sepharose 4B  (Pharmacia Biotech, Milton Key- 
nes,  UK)  was  swollen and  equilibrated in  100  mM  phosphate 
buffer, pH 7.0.  Der p  I  (150  /xg) was applied to the affinity col- 
umn, which was washed in 500 mM sodium chloride, 100 mM 
phosphate buffer, pH 7.0, and eluted with 500 mM sodium chlo- 
ride and  100  mM phosphate buffer,  pH  8.0,  containing 5  mM 
cysteine. Protein  elution was  monitored by UV  absorbance at 
280 nM, and protease activity was assessed using FITC-casein as a 
substrate. 
Der p 1-mediated Cleavage of CD23 from EBV-transformed B Cells 
and Immunofluorescence.  The EBV-transformed human B cell line 
BC5 was prepared from the PBMC of a normal blood donor us- 
ing  the  EBV-containing  supematant  from  the  B958  cell line. 
BC5  cells were washed three times in serum-free PBS, pH 8.0. 
The washed cells (10  6) were incubated with 5 ~g/m1-1 ofDerp I 
for 1 h at 37~  Inhibitors were used as already described. Direct 
immunofluorescence was performed by standard methods using 
FITC-conjugated anti-CD23  mAb  (BU38,  generously donated 
by  Roger  Drew,  The  Binding  Site  Ltd.,  Birmingham,  UK), 
FITC-conjugated anti-CD20 (Dako Ltd., High Wycombe, UK), 
or FITC-conjugated anti-human Ig (Dako UK). 
Indirect immunofluorescence was performed by standard methods 
using mAbs specific for monomorphic determinants of HLA-DR 
(L243,  ATCC  HB55),  HLA-DP  (B721.2),  and  HLA-DQ 
(SPLV.3, generously donated by Dr. Hergen Spits of the Nether- 
lands  Cancer  Institute,  Amsterdam,  Netherlands),  followed by 
FITC-conjugated goat anti-mouse Ig. Cells were analyzed using 
a  flow  cytometer  (on  FACScan|  Beckton  Dickinson  &  Co., 
Mountain View, CA). 
Results  and Discussion 
Purification of Derp I.  Der p  I was immunoaflfinity puri- 
fied  using  the  anti-mite  group  I  allergen-specific  mAb 
4C1. The purified enyzme allergen resolved as a single 25- 
27-kD  band  on  SDS-polyacrylamide gels.  Casein  zymo- 
grams of the same material showed a single proteolytic spe- 
cies coincident with the 25-27-kD protein (Fig. 1 a). 
Characterization  of the Mechanistic  Class of Der p  I.  Based 
on sequence analysis, Der p  I is often described as a cysteine 
Figure 1.  Purification ofDerp I and characterization 
of protease activity. (a) Affinity-purified Der p  I  re- 
solved as  a  25-27-kD  proteolytic  species on  SDS- 
PAGE and casein zymograms. (b) Pure Derp I was sen- 
sitive to the cysteine and serine protease inhibitors, 5 
FM E64 (m) and 50 tiM APMSF (k~), but not to in- 
hibitors of metallo- or aspartic proteases, 1 mM 1,10- 
phenanthroline ( [] ), 10 rnM EDTA ([]), and 1 IxM 
pepstatin-A (l'q). 
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Figure 2.  Cysteine and serine protease activities of Der p I purified by 
immuno- and active site affinity chromatography. (a) A~er immunoaffin- 
ity purification, further active site affinity chromatography ofDerp I con- 
firmed that cysteine and serine protease activities were properties of the 
same protein. All Derp I loaded bound to thiot-Sepharose 4B in 100 mM 
phosphate buffer, pH 7.0 (A), none of the protein (￿9  was desorbed by 
washing with  100 mM phosphate buffer, pH 7.0, and 500 mM sodium 
chloride (B). All the protein applied bound to the column and was eluted 
with  100 mM phosphate buffer, pH 8.0, and 500 mM sodium chloride 
containing 5 m/Vl cysteine (C). The tingle peak of eluted protein resolved 
at 25-27  kD, and using a FITC-casein substrate (O), contained mixed 
cysteine~serine protease activity, (b) as judged by sensitivity to  E64  (5 
b~M, i)  and APMSF (50  txM, k~) and  insensitivity to  1 mM  t,10- 
phenanthroline (D), 10 mM EDTA ([~) and 1 btM pepstatin-A ([]). 
protease  (16).  The  mechanistic  class of Der p  I,  however, 
has  not  been  rigorously  evaluated  experimentally.  Using 
the  fluorogenic  substrate  FITC-casein  and  irreversible 
class-specific protease inhibitors, we determined the class of 
protease to which Der p  I  belongs.  The activity of Der p  I 
was  inhibited by the  cysteine protease  inhibitor E64,  the 
serine  protease inhibitor APMSF,  but  not  by the  aspartic 
protease inhibitor pepstatin A  or the metalloprotease inhib- 
itors EDTA and 1,10-phenanthroline  (Fig. 1 b); suggesting 
that Derp I exhibits an unusual mixed cysteine-serine pro- 
tease  activity.  To  determine  whether  the  cysteine  and 
serine activities of immunoaffinity-purified Der p I could be 
separated, we further purified Der p  I by active site affinity 
chromatography  using  activated  thiol-Sepharose  4B.  M1 
the  Der p  I  loaded onto  the  column  was  absorbed by the 
thiol-Sepharose 4B,  and no protein was  eluted during the 
washing steps. Bound material was eluted with 5  mm cys- 
teine and characterized using class-specific protease inhibi- 
tors. As before, the activity of Der p  I was inhibited by the 
cysteine protease inhibitor E64  and the serine protease in- 
hibitor APMSF, but not by the aspartic protease inhibitor 
pepstatin A  or  the  metalloprotease inhibitors EDTA  and 
1,10-phenanthroline (Fig. 2). This confirms that even after 
sequential  purification  by  two  different  criteria,  Der p  I 
maintains  a  characteristic  mixed  cysteine~serine  protease 
activiw. 
Our  finding that  Der p  I  exhibits a  mixed mechanistic 
class  based  on  inhibitor  sensitivity is  not  unique;  similar 
dual activities have been reported for a fungal protease (54) 
and a proteasome (55).  Unlike the rnultisubunit proteases, 
however,  a  structural  model of Der p  I  based on  the  cys- 
teine  proteases  papain,  actinidin,  and  papaya  protease 
1540  Derp I Cleaves CD23 
100- 
80 
('~)1 
.......................... 
0  10  100  1000 
Recombinant  human 
ct  l-antiproteaae  (nM) 
Figure 3.  Der p I is inhibited by endogenous antiprotease oq-antipro- 
tease. Recombinant human Ixl-antiprotease inhibited Derp I (i) and the 
serine protease trypsin (I) but had no effect on the cysteine protease pa- 
pain (0). 
shows that the enzyme has only a single active site (56).  It 
is, therefore, probable that  other characteristics of the  en- 
zyme or inhibitors are responsible for the apparently mixed 
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Figure 4.  Der p I cleaves CD23 from the surface of EBV-transformed 
human B cells. (a) Cleavage of CD23 was dependent on the concentra- 
tion ofDerp I and (b) the period of incubation. 8 
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Figure  5.  The  mixed  cysteine- 
serine  protease  activity  of Der p  I 
cleaves  CD23.  In  the  presence  of 
Der p  I  (m), cleavage of CD23 was 
inhibited by E64 (a) and APMSF (b) 
but  not  by  1,10-phenanthroline  (c) 
or pepstatin-A (d). None of the in- 
hibitors  themselves, in  the  absence 
of Der p  I, had any effect on the ex- 
pression of CD23 (O). 
mechanistic  class  of the  enzyme  when  determined  with 
class-specific inhibitors. 
Most cysteine proteases are optimally active at a slightly 
acidic or neutral pH (57).  In this respect, Der p I is unusual 
because optimal activity is seen at pH 8.0 (data not shown), 
in keeping with the estimated pH of the posterior midgut 
of the mite (58). At pH 8.0, it is possible that the properties 
of the inhibitors and characteristics of the active site of the 
protease are different from those at the lower pH at which 
other cysteine proteases are assayed, perhaps accounting for 
the  apparent  mixed  cysteine-serine  protease  activity  ob- 
served with Der p I. 
Innate Antiproteases May Protect Against Sensitization  to Der 
p I.  Since Der p  I exhibits serine protease activity, we ex- 
amined whether al-antiprotease, an important inhibitor of 
serine proteases in the  respiratory tract,  constitutes  an in- 
nate form of defense to damage and allergic sensitization by 
proteolytically active  Der p  I.  We  have,  therefore,  com- 
pared the ability of recombinant human cq-antiprotease to 
inhibit  the activity of Der p  I  and the  archetypal cysteine 
and serine proteases papain and trypsin. 
Using  FITC-casein as  a  substrate,  recombinant human 
al-antiprotease was found to inhibit both Der p  I and the 
serine  protease  trypsin  but  had  no  effect on  the  cysteine 
protease papain (Fig.  3). 
Under circumstances in which antiprotease defenses are 
reduced, proteolytically active 'Der p I in inhaled mite feces 
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may cause focal injury to the ciliated epithelium. This may 
not only delay clearance of the allergen and induce chemo- 
tactic cytokine and chemokine secretion by epithelial cells 
(59), but it may also allow Derp I and other allergens in the 
fecal pellet access to the underlying immune system. Effi- 
cient inhibition ofDerp I by oq-antiprotease and other res- 
piratory tract antiproteases  (42)  may thus  be important in 
preventing allergic sensitization. 
This series of events may contribute to immune sensiti- 
zation,  but it does not explain why Der p  I  so frequently 
causes allergic immunity.  Allergic  immune  responses may 
be  regulated  by  changes  in  Thl  and  Th2  subsets  or  by 
mechanisms within the IgE network. Because the release of 
CD23 from the cell surface and its appearance in the plasma 
are regulated by a process that may involve proteolysis (37), 
we examined whether the proteolytic activity ofDerp I in- 
terferes with the expression of CD23, a critical regulator of 
the IgE network. 
Der p I  Cleaves CD23,  a Critical Regulator of the IgE Net- 
work. EBV transformed human B cells express high levels of 
CD23; this provides a convenient source of native, cell-as- 
sociated CD23 for use as a substrate. When incubated with 
Derp I, CD23 was removed from the surface of the EBV B 
cells in a time- and concentration-dependent manner (Fig. 
4).  In accordance with  our data  showing  the  mixed cys- 
teine-serine activity of Der p  I, the cleavage of CD23 was 
inhibited  by the  irreversible class-specific protease  inhibi- 0  :t[7  
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Figure 6.  Cleavage  of CD23 is inhibited by ~,-antiprotease. Cleavage 
of CD23 from the surface of EBV-transformed human B cells by Derp I 
was inhibited by the respiratory tract antiprotease cel-antiprotease (I). 
The eq-antiprotease alone in the absence of Der p I had no effect on the 
expression of CD23 (0). 
tots  E64  and APMSF  (Fig.  5,  a  and  b),  but not by  1,10- 
phenanthroline  or pepstatin  A  (Fig.  5,  c and  d),  thus  sug- 
gesting  that  the  unusual  mixed  cysteine--serine  activity 
characteristic  of Der p  I  was  responsible  for  cleavage  of 
CD23  from the  B  cell  surface.  Interestingly,  Cel-antipro- 
tease also inhibited cleavage of CD23 by Derp I, suggesting 
that disruption of the IgE network may be prevented by an 
efficient pulmonary antiprotease &fence system (Fig. 6).  It 
is  interesting  to  speculate  that  the  unique  structure  of 
CD23  among  the  Ig  Fc  receptors  presents  an  accessible 
cleavage site for Der p  I that is not present in other Fc re- 
ceptors that belong to the Ig superfamily. 
The  reproducible  induction  of  allergic  immune  re- 
sponses by Der p  I suggests that cleavage of CD23 may be 
selective,  as indiscriminate  cleavage of all  cell surface pro- 
teins  would  have  more  severe  consequences  for the  im- 
mune  system.  We  therefore  determined  whether  Der p  I 
preferentially cleaved CD23 from the cell surface by exam- 
ining the  expression  of several  o~ther B  cell surface  mole- 
cules on EBV-transformed B cells after incubation with Der 
p  I. The expression levels of CD20,  surface Ig, HLA-DR, 
HLA-DP, and  HLA-DQ  were  unchanged  by incubation 
//,oo  / o/ ,o" 
Cell surface antigen 
Figure 7.  Derp  [ cleaves CD23 selectively. The expression of five cell 
surface molecules, in addition to CD23, were examined atier incubation 
at 37~  for 1 h in the presence (ll) and absence (k~) of Derp I. The fail- 
ure ofDerp I to cleave any cell surface molecule apart from CD23 dem- 
onstrated the selectivity of  cleavage. 
with  Der p  I,  confirming  that  Der p  I  selectively  cleaves 
CD23  (Fig.  7).  This  result  is  particularly  interesting  be- 
cause HLA-DR is reported to be noncovalently linked to 
CD23 (60). 
This  study suggests  a  mechanism by which house  dust 
mites  may provoke  powerful  allergic  immune  responses. 
Reduced  antiprotease  defense  caused by pollution  or in- 
flammation may allow Derp I to injure the respiratory epi- 
thelium and access the immune system. Here, Der p  I may 
selectively alter the level of expression  of CD23,  a critical 
regulator of the IgE network, by causing the loss of an IgE 
immune  complex-mediated  feedback  inhibition  pathway 
and the enhancement ofa sCD23-mediated IgE promoting 
pathway,  which may result in high IgE responses.  Several 
parasites  that  provoke  high  protective  IgE  responses  (61) 
are also known to expel or secrete proteolytic enzymes (52), 
and it has already been suggested that in such cases,  a simi- 
lar  mechanism involving CD23  cleavage by these  exoge- 
nous proteases  may be responsible  for inducing protective 
allergic rather than harmful allergic immune responses (62). 
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